ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Discovery

Lilly and Sitryx sign immunotherapy pact

by Michael McCoy
April 3, 2020 | APPEARED IN VOLUME 98, ISSUE 13

 

Eli Lilly and Company will invest $60 million in cash and stock in Sitryx, a British biotech firm developing immuno-oncology and immuno-inflammation drugs that work by regulating cell metabolism. Under the pact, Lilly gets the right to develop four Sitryx therapies, including its two lead projects. Sitryx launched in 2018 with $30 million in funding from GlaxoSmithKline and others.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment